![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1402601
Ç÷°ü Æó¼â ÀåÄ¡ ½ÃÀå : Á¦Ç° À¯Çüº°, ¾×¼¼½ºº°, ±¸¸Û »çÀÌÁ, ÃÖÁ¾ »ç¿ëÀÚº° ¹× Áö¿ªº°Vascular Closure Device Market, by Product Type, By Access, By Hole Size By End User and by Region |
¼¼°èÀÇ Ç÷°ü Æó¼â ÀåÄ¡ ½ÃÀå ±Ô¸ð´Â 2023³â 12¾ï 8,380¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2030³â¿¡´Â 19¾ï 4,320¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ Áß CAGRÀº 6.1%·Î Àü¸ÁµË´Ï´Ù.
º¸°í ¹üÀ§ | º¸°í¼ ¼¼ºÎÁ¤º¸ | ||
---|---|---|---|
±âÁسâ | 2022³â | ½ÃÀå ±Ô¸ð(2023³â) | 12¾ï 8,380¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ | 2018-2021³â | ¿¹Ãø ±â°£ | 2023-2030³â |
¿¹Ãø ±â°£ÀÇ CAGR | 6.10% | ½ÃÀå ±Ô¸ð ¿¹Ãø(2030³â) | 19¾ï 4,320¸¸ ´Þ·¯ |
Ç÷°ü Æó¼â ÀåÄ¡´Â Ç÷°ü Á¶¿µ¼ú ¹× Ç÷°ü ¼ºÇü¼ú°ú °°Àº ½ÉÀåÇ÷°ü Ä¡·á ÈÄ µ¿¸Æ õÀÚ¸¦ ¹ÐºÀÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ±â°èÀû ¶Ç´Â »ý¹°ÇÐÀû ¼ö´Ü¿¡ ÀÇÇØ ÀÚ¿¬ÀûÀÎ ÀÀ°í¸¦ ÃËÁøÇÔÀ¸·Î½á õÀÚ ºÎÀ§ÀÇ ÃâÇ÷À» ¸·´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¼¼°è Ç÷°ü Æó¼â ÀåÄ¡ »ç¿ë·®Àº ¼¼°è ÀÎÅͺ¥¼Å³Î ½ÉÀå º´ÇÐ ¹× ¹æ»ç¼± Ä¡·áÀÇ ¼ºÀå°ú ÇÔ²² Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ȯÀÚÀÇ ÄèÀû¼º Çâ»ó, ÀÔ¿ø ±â°£ ´ÜÃà, ¼öµ¿ ¾Ð¹Ú ¹æ¹ý¿¡ ºñÇØ ÇÕº´Áõ ¹ß»ý·ü ÀúÇÏ·Î Ç÷°ü Æó¼â ÀåÄ¡´Â Ç÷°ü Á¢±Ù ºÎÀ§ °ü¸®¿¡ ÇʼöÀûÀÔ´Ï´Ù.
¼¼°èÀÇ Ç÷°ü Æó¼â ÀåÄ¡ ½ÃÀåÀº Àα¸ ¿ªÇÐ º¯È¿¡¼ ±â¼ú Áøº¸¿¡ À̸£±â±îÁö ´Ù¾çÇÑ ¿äÀÎÀÌ °ãÄ¡°í Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ ¼ºÀå¿¡ Å©°Ô ±â¿©ÇÏ´Â °ÍÀº »ý¸®Àû ³ëÈ·Î ½ÉÇ÷°ü Áúȯ¿¡ °É¸®±â ½¬¿î ³ëÀÎ Àα¸ Áõ°¡ÀÔ´Ï´Ù. ³ëÀÎ Àα¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÉÇ÷°ü ÁúȯÀÇ ¹ß»ý·üµµ Áõ°¡ÇÏ¿© Áø´Ü ¹× Ä¡·á ÀýÂ÷ ÈÄ È¿°úÀûÀÎ Ç÷°ü Æó¼â ÀåÄ¡¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. µ¿½Ã¿¡ °Ç° °ü¸® ºÎ¹® Àüü¿¡¼ Àúħ½À ¼ö¼ú(MIS)·ÎÀÇ ÀüȯÀÌ ÇöÀúÇØÁö°í ÀÖ½À´Ï´Ù. MIS ¼ö¼úÀº ÀüÅëÀûÀÎ °³º¹ ¼ö¼ú¿¡ ºñÇØ °¨¿° À§ÇèÀ» ÁÙÀ̰í ÀÔ¿ø ±â°£À» ´ÜÃàÇϸç ȯÀÚÀÇ È¸º¹À» °¡¼ÓÈÇÕ´Ï´Ù. Ç÷°ü Æó¼â ÀåÄ¡´Â ½Å¼ÓÇÑ ÁöÇ÷, º¸Çà ½Ã°£ ´ÜÃà, ȯÀÚÀÇ Æí¾ÈÇÔ Çâ»ó µî ÀÌµé ¼ö¼ú¿¡ ÀÖ¾î¼ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù.
±â±¸ ±â¼úÀÇ Áøº¸´Â ¶ÇÇÑ ¸Å¿ì Áß¿äÇϸç, º¸´Ù ³ôÀº È¿´É°ú ÀýÂ÷ ÈÄ ÇÕº´Áõ À§ÇèÀ» °¨¼Ò½ÃŰ´Â ±â±¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù. µðÀÚÀΰú ¼ÒÀçÀÇ °³·®¿¡ ÀÇÇØ ¹ÐÆó¼ºÀÌ Çâ»óµÇ¾î, ´Ù¾çÇÑ ÇØºÎÇÐÀû Çü»óÀ̳ª õÀÚ »çÀÌÁî¿¡ ÀûÇÕÇÑ Á¦Ç°ÀÌ Åº»ýÇß½À´Ï´Ù. ¹Ý¸é¿¡ ÀÌ·¯ÇÑ Ã·´Ü Àåºñ¿Í °ü·ÃµÈ ³ôÀº ºñ¿ëÀº º¸±Þ À庮ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ƯÁ¤ ÇコÄÉ¾î ½Ã½ºÅÛ¿¡¼ÀÇ »óȯ ºÎÁ·Àº ÀÌ ¹®Á¦¸¦ ´õ¿í ¾ÇȽÃÄÑ È¯ÀÚ°¡ ÀÌ·¯ÇÑ ±â¼úÀ» ÀÌ¿ëÇÏ±â ¾î·Æ°Ô Çϰí ÀÖ½À´Ï´Ù. ¼öÀÛ¾÷À¸·Î ÀÎÇÑ ¾Ð¹Ú°ú °°Àº ÁöÇ÷À» ´Þ¼ºÇϱâ À§ÇÑ ±âÁ¸ÀÇ ´ëü ¼ö´ÜÀº Á¸ÀçÇÏÁö¸¸, ȸº¹¿¡ ½Ã°£ÀÌ °É¸®°Å³ª ÇÕº´ÁõÀÇ À§ÇèÀÌ ³ô¾ÆÁö´Â °æ¿ì°¡ ¸¹½À´Ï´Ù.
ÀÌ ½ÃÀåÀº ƯÈ÷ ÇコÄɾ ´ëÇÑ ÅõÀÚ¿Í ÇコÄɾî ÀÎÇÁ¶óÀÇ °È°¡ ÁøÇàµÇ°í ÀÖ´Â ½ÅÈï±¹¿¡¼ Å« ºñÁî´Ï½º ±âȸ·Î Ãູ¹Þ°í ÀÖ½À´Ï´Ù. °æ Ä«Å×ÅÍ ´ëµ¿¸Æ ÆÇ¸· ġȯ¼ú(TAVR)°ú °°Àº º¹ÀâÇÑ ÀýÂ÷¿¡¼ ÀϹÝÀûÀ¸·Î »ç¿ëµÇ´Â »ýºÐÇØ¼º ¹°Áú·Î ¸¸µé¾îÁø °Í°ú °°Àº ÇöÀç ÁøÇà ÁßÀÎ ½Å±Ô ÀåÄ¡ÀÇ °³¹ß¿¡´Â Å« °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. Àü¹ÝÀûÀ¸·Î ºñ¿ë ¹× »óȯ ¹®Á¦¿Í °°Àº °úÁ¦´Â ¿©ÀüÈ÷ ³²¾Æ ÀÖÁö¸¸ ±â¼ú ¹ßÀü°ú MIS¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í °°Àº Ç÷°ü Æó¼â ÀåÄ¡ÀÇ ÀåÁ¡Àº ¾ÕÀ¸·Îµµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
¿¹¸¦ µé¾î, 2021³â 1¿ù, ´õ ³ªÀº ȯÀÚ °á°ú¸¦ ÃËÁøÇÏ´Â Çõ½ÅÀûÀÎ ÀÇ·á ¼Ö·ç¼Ç Á¦°ø¿¡ ÁÖ·ÂÇÏ´Â ÀÇ·á ±â¼ú ȸ»çÀÎ Haemonetics CorporationÀº Ç÷°ü Æó¼â ½Ã½ºÅÛÀÇ Á¦Á¶¾÷üÀÎ ºñ°ø°³ ȸ»ç Cardiva Medical, Inc.¸¦ ÀμöÇÏ´Â Á¤½Ä °è¾àÀ» ü°áÇß½À´Ï´Ù.
The global vascular closure device market size is expected to reach US$ 1,943.2 Mn by 2030, from US$ 1,283.8 Mn in 2023, at a CAGR of 6.1% during the forecast period.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023: | US$ 1,283.8 Mn |
Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
Forecast Period 2023 to 2030 CAGR: | 6.10% | 2030 Value Projection: | US$ 1,943.2 Mn |
Vascular closure devices help seal arterial punctures after a cardiovascular procedure such as angiography or angioplasty. They help stop bleeding at the puncture site by accelerating natural clotting through mechanical or biological means. The global usage of vascular closure devices has been increasing with growth in interventional cardiology and radiology procedures worldwide. Improved patient comfort, reduced hospital stay times, and lower complication rates compared to manual compression methods have made vascular closure devices an integral part of vascular access site management.
The global vascular closure device market is growing substantially, propelled by a confluence of factors ranging from demographic shifts to technological progress. A significant contributor to this growth is the rising geriatric population which is more susceptible to cardiovascular diseases due to physiological aging. As the elderly population grows, so does the incidence of cardiovascular conditions, thereby increasing the demand for effective vascular closure devices following diagnostic and therapeutic procedures. Simultaneously, a notable shift towards minimally invasive surgeries (MIS) across the healthcare sector. MIS procedures reduce the risk of infection, shorten hospital stays, and speed up patient recovery times compared to traditional open surgeries. Vascular closure devices play a key role in these procedures by providing rapid hemostasis, reducing time to ambulation, and enhancing patient comfort.
Advancements in device technology have also been pivotal, leading to devices that offer greater efficacy and a reduced risk of post-procedure complications. Enhanced designs and materials have yielded products with improved sealing capabilities and compatibility with various anatomies and puncture sizes. On the other side of the spectrum, the high costs associated with these advanced devices can act as a barrier to their widespread adoption. The lack of reimbursement in certain healthcare systems further exacerbates this issue, making it challenging for patients to access these technologies. While existing alternatives for achieving hemostasis, such as manual compression, exist, they often come with longer recovery times and elevated risks of complications, thereby providing an opening for the adoption of advanced vascular closure devices.
The market is ripe with opportunities, especially within emerging economies that are currently witnessing increased healthcare investments and enhancements to their healthcare infrastructure. The significant potential in the ongoing development of novel devices, including those made from biodegradable materials, commonly used in complex procedures like transcatheter aortic valve replacement (TAVR).Overall, while challenges like cost and reimbursement issues persist, the benefits of vascular closure devices, including the advancements in technology and rising demands for MIS, are likely to continue to drive market growth.
For instance, in January 2021, Haemonetics Corporation, a medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, entered into a definitive agreement to acquire privately-held Cardiva Medical, Inc., a manufacturer of vascular closure systems.
Global Vascular Closure Device Market